Filing Details

Accession Number:
0001209191-16-126266
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-07 16:41:46
Reporting Period:
2016-06-07
Filing Date:
2016-06-07
Accepted Time:
2016-06-07 16:41:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1539029 Clearside Biomedical Inc. CLSD Pharmaceutical Preparations (2834) 452437375
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1664690 A. Charles Deignan C/O Clearside Biomedical, Inc.
1220 Old Alpharetta Road, Suite 300
Alpharetta GA 30005
Chief Financial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2016-06-07 4,261 $0.00 62,291 No 4 C Direct
Common Stock Acquisiton 2016-06-07 470 $0.02 62,761 No 4 X Direct
Common Stock Disposition 2016-06-07 2 $7.00 62,759 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 X Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B Preferred Stock Disposition 2016-06-07 9,375 $0.00 4,261 $0.00
Common Stock Warrant to Purchase Common Stock (right to buy) Disposition 2016-06-07 470 $0.00 470 $0.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 2014-04-28 No 4 X Direct
Footnotes
  1. Represents shares received upon conversion of shares of Series B Preferred Stock.
  2. Effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock automatically converted into 0.454545 shares of the Issuer's common stock. The Series B Preferred Stock had no expiration date.
  3. On June 7, 2016, the reporting person exercised a warrant to purchase 470 shares of Issuer's common stock for $0.022 per share. The reporting person paid the exercise price on a cashless basis, resulting in the issuer's withholding of 2 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 468 shares.
  4. This warrant would have expired upon the closing of the Issuer's initial public offering.